14 Jan, EOD - Indian

SENSEX 76499.63 (0.22)

Nifty 50 23176.05 (0.39)

Nifty Bank 48729.15 (1.43)

Nifty IT 43061.15 (-2.13)

Nifty Midcap 100 53676.5 (2.45)

Nifty Next 50 63084.1 (2.61)

Nifty Pharma 22203.9 (1.37)

Nifty Smallcap 100 17257.8 (1.98)

14 Jan, EOD - Global

NIKKEI 225 38474.3 (-1.83)

HANG SENG 19219.78 (1.83)

S&P 5890.25 (0.06)

LOGIN HERE

companylogoAarti Drugs Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 524348 | NSE Symbol : AARTIDRUGS | ISIN : INE767A01016 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
17-Oct-2024 24-Oct-2024 Quarterly Results AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve Audited financial results for the quarter and half year ended September 30 2024 Financial Results for the quarter and half year ended September 30, 2024 (As per BSE Announcement Dated on 24/10/2024)
21-Aug-2024 26-Aug-2024 Buy Back AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/08/2024 inter alia to consider and approve the proposal of Buyback of equity shares of the Company Outcome of the Board meeting dated August 26, 2024 (As per BSE Announcement Dated on 21/08/2024)
19-Jul-2024 26-Jul-2024 Accounts AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve This is to inform you that next Board Meeting of the Board of Directors of the Company is scheduled to be held on Friday July 26 2024 to consider approve and take on record Audited Financial Results for the Quarter ended June 30 2024. Outcome of the Board meeting (As per BSE Announcement Dated on 26/07/2024)
26-Apr-2024 03-May-2024 Accounts AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/05/2024 inter alia to consider and approve Audited Financial Results for the Quarter and year ended March 31 2024. Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2024 and Outcome of the Meeting of Board of Directors held on May 3, 2024. (As Per BSE Announcement Dated on 03.05.2024)
29-Mar-2024 29-Mar-2024 Change in Directors Appointment of Independent Directors
17-Jan-2024 24-Jan-2024 Quarterly Results AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2024 inter alia to consider and approve Quarterly Audited Financial results for the period ended December 31 2023 and Interim Dividend for FY 2023-24 if any Board of Directors of the Company at its Meeting held on Wednesday, January 24, 2024, has declared the Interim Dividend of Re. 1/- (Rupee One) (@10%) per Equity share of Rs. 10/- each for the financial year 2023-24. Please note that as per Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, Tuesday, February 6, 2024 has been fixed as Record Date' for the purpose of payment of Interim Dividend. Financial Results and Declaration of Interim Dividend (As Per BSE Announcement Dated on 24.01.2024)
12-Oct-2023 19-Oct-2023 Quarterly Results AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/10/2023 inter alia to consider and approve Audited Financial Results for the quarter and half year ended September 30 2023 Financial Results for the quarter and half year ended September 30, 2023 Financial Results for the quarter and half year ended September 30, 2023 (As Per BSE Announcement Dated on 19.10.2023)
14-Jul-2023 21-Jul-2023 Accounts AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2023 inter alia to consider and approve Audited Financial Results and the proposal of buyback Financial Results for the quarter ended June 30, 2023 Board approved the Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2023 and Buy-back of Equity Shares The Board of Directors has determined the Record date for the buy-back as August 4, 2023 Board approved the Buy-back (As Per BSE Announcement dated on 21.07.2023)
23-Apr-2023 29-Apr-2023 Accounts AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2023 inter alia to consider and approve Audited Financial Results for the Quarter and year ended March 31 2023 Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2023 Appointment of Statutory Auditor (As Per BSE Announcement dated on 29.04.2023)
20-Jan-2023 27-Jan-2023 Quarterly Results AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2023 inter alia to consider and approve - Audited Financial Results for the Quarter and Nine months ended December 31 2022 - Interim dividend for the FY 2022-23 if any. We wish to inform you that the Board of Directors of the Company at its Meeting held on Friday, January 27, 2023, has declared the Interim Dividend of Re. 1/- (Rupee One) (@10%) per Equity share of Rs. 10/- each for the financial year 2022-23. Audited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2022. (As Per BSE Announcement Dated on 27.01.2023)
13-Oct-2022 20-Oct-2022 Quarterly Results AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2022 inter alia to consider and approve Audited Financial Results for the Quarter and half year ended September 30 2022 Audited Financial Results for the Quarter and half Year ended September 30, 2022 (As Per BSE Announcement Dated on 20/10/2022)
26-Sep-2022 26-Sep-2022 Change in Directors based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its meeting held today approved the re-appointed of Shri Rashesh C. Gogri (DIN: 00066291) as the Managing Directors.
21-Jul-2022 27-Jul-2022 Quarterly Results Quarterly Results AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2022 ,inter alia, to consider and approve Audited Financial Results for the Quarter ended June 30, 2022. Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2022. Outcome of the Meeting of the Board of Directors of Novartis India Limited held today i.e. Wednesday, July 27, 2022 (As Per BSE Announcement Dated on 27.07.2022)
02-May-2022 09-May-2022 Accounts Audited Results AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2022 ,inter alia, to consider and approve and take on record Audited Financial Results for the Quarter and year ended March 31, 2022. We wish to inform you that Board of Directors at its Meeting held on Monday, May 9, 2022, approved the Audited Financial Results of the Company (Standalone and Consolidated) for the Quarter and Year ended March 31, 2022. In this regards we enclose; i. Statement showing the Financial Results (Standalone and Consolidated), ii. Statement of Assets and Liabilities (Standalone and Consolidated), iii. Cash Flow Statement (Standalone and Consolidated) iv. Auditor's Report on the Financial Results (Standalone and Consolidated), v. Declaration in respect of Audit reports with unmodified opinion for the Financial Year ended March 31, 2022 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its meeting held today appointed Prof. Bhaskar Narayan Thorat (DIN: 01293824) and CA Neha Rajen Gada (DIN: 01642373) as an Additional Directors in the category of an Independent Director of the Company with effect from May 9, 2022 for the period of three years subject to approval of the Shareholders of the Company. (As Per BSE Announcement dated on 09.05.2022)
25-Jan-2022 31-Jan-2022 Accounts AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022 inter alia to consider and approve and take on record Audited Financial Results for the Quarter and Nine months ended December 31 2021 and consider and declare Interim dividend for the FY 2021-22 if any. We wish to inform you that Board of Directors of the Company at its Meeting held on Monday, January 31, 2022, has declared the Interim Dividend Rs. 1/- (Rupee One) (@10%) per Equity share for the financial year 2021-22. Please note that as per Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, Thursday, February 10, 2022 has been fixed as 'Record Date' for the purpose of payment of Interim Dividend. (As Per BSE Announcement Dated on 31.01.2022)
1 2 

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +